Freenome enters the public markets via $330M SPAC deal

Freenome's SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review. If approved, the Freenome blood test would compete against Guardant Health's liquid biopsy, Shield.

Editor's Pick

Top Story Liquid Biopsy Firm Freenome Finds a Way to the Public Markets via $330M SPAC Merger Freenome's SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review. If approved, the Freenome blood test would compete against Guardant Health's liquid biopsy, Shield. Sponsored The Power of One: Redefining Healthcare with an AI-Driven Unified Platform Presented by Greenway Health In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation. Learn More

Featured News

Senators Introduce Bipartisan Bill to Increase Oversight of PBMs A bipartisan Senate bill would boost transparency and oversight of pharmacy benefit managers by changing how they're paid, expanding reporting requirements and strengthening protections for pharmacies and taxpayers. How LG Is Moving Into Clinical Workflows As it deepens its push into healthcare, LG is developing more tools and workstations aimed at supporting clinical workflows. National sales leader Jim Salamon said the company's innovations are designed around clinician needs, such as the desire for more lifelike color representation and lightweight displays that can be set up easily for home use. Call Center Lessons: Streamline the Challenges and Celebrate More Wins By building skills in operations and developing a close-knit team who show up to work with hearts of empathy and tenacity to problem solve, the issues become fewer and further between. Open Enrollment: Why Rising Premiums Are Forcing Healthcare Organizations to Bet on AI and Automation Open enrollment 2026 marks a turning point in U.S. healthcare. The cost pressures are no longer cyclical; they are structural. For payers and providers alike, the challenge is clear: we must modernize operations, not just manage costs.

Video   What Are Investors Looking For In Mental Health Startups? At a recent behavioral health tech conference, Emily Durfee, a partner at Healthworx Ventures, shared her thoughts on how to differentiate mental health startups in an increasingly crowded market. She said it's important to figure out if the startup is solving a key problem for their customer — whether that's a provider, payer, employer or consumer.

Sponsored As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities Presented by Munich Re Specialty – North America In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play. Learn More

Resources

MedCity FemFwd: How Women's Health Advocates Is Pushing for Change In this episode, we're joined by Liz Powell, founder of Women's Health Advocates. We discussed the organization's policy priorities in the women's health space. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe